The Food and Drug Administration (FDA) has expanded the approval of Inspire therapy (Inspire Medical Systems) to include patients aged 18 to 21 years with moderate to severe obstructive sleep apnea (OSA) who are unable to use continuous positive airway pressure (CPAP). Previously, the therapy was only approved for patients 22 years of age and…
Response more likely with favorable nonpharyngeal traits, moderate pharyngeal collapsibility
Jazz Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
In addition to known predictors of apnea, diabetes-related foot disease, insulin treatment up risk
Among OSA patients, risk for developing gout is highest one to two years after the index date
A dose-dependent response was seen at week 1 and was maintained during the rest of the study period. They also observed improvement on the Patient Global Impression of Change for all doses except 37.5mg (P<0.05).
Continuous positive airway pressure (CPAP) remains the mainstay of medical treatment for OSA.
Care provided by NSSs and SSPs resulted in similar quality of life, adherence, and symptom scores (low-strength evidence), based on results from five randomized trials and three observational studies (1,515 participants; mean age, 52 years; 68% male).
The implantable device works by stimulating a nerve in the chest that is involved in transmitting signals to the diaphragm to stimulate breathing.
